Proprietary R&D

In-house R&D on development of novel platform technologies and drug discovery
In addition to providing R&D services to industrial clients, ACIES BIO also runs an internal R&D pipeline, aimed primarily at developing innovative technological platforms and processes for improved production of pharmaceutical drugs. These proprietary technology platforms can often be included in the scope of our R&D services to improve the efficiency of expression or production of a target metabolite.

a) Industrial heterologous expression systems for production of secondary metabolites and heterologous proteins / enzymes;

b) Advanced gene cloning tools for manipulation and efficient delivery of extremely large DNA fragments into expression hosts;

c) Drug discovery development of novel compounds focusing on anti-infective, anticancer, anti-inflammatory and neurodegenerative applications.

d) Innovative sustainable eco-bioprocesses




Acies Bio received the “Jesenko Award” from Biotechnical Faculty of University of Ljubljana. The award recognizes institutions for their outstanding research work in the field of biotechnology.

ABCloneTM is fast and efficient solution for cloning of large natural and synthetic DNA fragments. We provide ABCloneTM as a stand alone service for getting quickly your long DNA fragment sub-cloned into plasmid vector of your choice.

More >>
Scientists at ACIES BIO made a breakthrough innovation: high-value technology that uses unique and economic bioprocess to convert acid waste whey from dairy factories into high value animal feed products (vitamin B12) and clean water in the same process. Check out Whey2Value!



More >>
European Medicines Agency (EMA) granted orphan medicinal product designation to its lead compound CAB1803 for Pantothenate-kinase-associated neurodegeneration (PKAN)

More >>
Within H2020 SME Innovation Associate project we invite a “Disease Model Development Manager” to join our team.




More >>